Capsules containing high doses of levodopa for pulmonary use
First Claim
1. A capsule for use in an inhalation device filled with a dry powder comprising levodopa, a salt and a phospholipid and having a working density between about 0.02 to about 0.1 g/cm3, and containing a capsule shell comprising hydroxypropyl methylcellulose (HPMC) and titanium dioxide, and wherein said capsule emits more powder comprising levodopa upon actuation of the inhalation device as compared to a capsule that comprises HPMC and is free of titanium dioxide;
- and wherein the capsule comprises from about 80% to about 95% levodopa.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.
38 Citations
14 Claims
-
1. A capsule for use in an inhalation device filled with a dry powder comprising levodopa, a salt and a phospholipid and having a working density between about 0.02 to about 0.1 g/cm3, and containing a capsule shell comprising hydroxypropyl methylcellulose (HPMC) and titanium dioxide, and wherein said capsule emits more powder comprising levodopa upon actuation of the inhalation device as compared to a capsule that comprises HPMC and is free of titanium dioxide;
- and wherein the capsule comprises from about 80% to about 95% levodopa.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
Specification